170 related articles for article (PubMed ID: 37611432)
1. Breast cancer vaccines; A comprehensive and updated review.
Al-Hawary SIS; Saleh EAM; Mamajanov NA; S Gilmanova N; Alsaab HO; Alghamdi A; Ansari SA; Alawady AHR; Alsaalamy AH; Ibrahim AJ
Pathol Res Pract; 2023 Sep; 249():154735. PubMed ID: 37611432
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Vaccines: Disappointing or Promising?
Zhu SY; Yu KD
Front Immunol; 2022; 13():828386. PubMed ID: 35154149
[TBL] [Abstract][Full Text] [Related]
3. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Arab A; Yazdian-Robati R; Behravan J
Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
[TBL] [Abstract][Full Text] [Related]
4. Progress in Vaccine Therapies for Breast Cancer.
Li X; Bu X
Adv Exp Med Biol; 2017; 1026():315-330. PubMed ID: 29282691
[TBL] [Abstract][Full Text] [Related]
5. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Benavides LC; Gates JD; Carmichael MG; Patil R; Holmes JP; Hueman MT; Mittendorf EA; Craig D; Stojadinovic A; Ponniah S; Peoples GE
Clin Cancer Res; 2009 Apr; 15(8):2895-904. PubMed ID: 19351776
[TBL] [Abstract][Full Text] [Related]
6. Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.
Pallerla S; Abdul AURM; Comeau J; Jois S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466691
[TBL] [Abstract][Full Text] [Related]
7. Anti-HER2 vaccines: new prospects for breast cancer therapy.
Ladjemi MZ; Jacot W; Chardès T; Pèlegrin A; Navarro-Teulon I
Cancer Immunol Immunother; 2010 Sep; 59(9):1295-312. PubMed ID: 20532501
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
[TBL] [Abstract][Full Text] [Related]
9. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.
Mohit E; Hashemi A; Allahyari M
Expert Rev Clin Immunol; 2014 Jul; 10(7):927-61. PubMed ID: 24867051
[TBL] [Abstract][Full Text] [Related]
11. HER2-Based Immunotherapy for Breast Cancer.
Cui N; Shi J; Yang C
Cancer Biother Radiopharm; 2018 Jun; 33(5):169-175. PubMed ID: 29874101
[TBL] [Abstract][Full Text] [Related]
12. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
[TBL] [Abstract][Full Text] [Related]
13. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
[TBL] [Abstract][Full Text] [Related]
14. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
16. HER2 dendritic cell vaccines.
Morse MA; Clay TM; Colling K; Hobeika A; Grabstein K; Cheever MA; Lyerly HK
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S164-72. PubMed ID: 12620155
[TBL] [Abstract][Full Text] [Related]
17. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
18. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG
J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923
[TBL] [Abstract][Full Text] [Related]
19. Toward a breast cancer vaccine: work in progress.
Emens LA; Jaffee EM
Oncology (Williston Park); 2003 Sep; 17(9):1200-11; discussion 1214, 1217-8. PubMed ID: 14569849
[TBL] [Abstract][Full Text] [Related]
20. The clinical development of vaccines for HER2
Costa RLB; Soliman H; Czerniecki BJ
Cancer Treat Rev; 2017 Dec; 61():107-115. PubMed ID: 29125981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
